Recent advances and novel agents for gastrointestinal stromal tumor (GIST)

Table 1 TKIs for imatinib-resistant GIST

Study Drug	Disease	Clinical Trial	Number of patients	Results	Status	Reference
Sunitinib	Imatinib-resistant	Phase 3	312	TTP 27 weeks	FDA Approved. On NCCN guidelines.	[38]
Sorafenib	Imatinib- and Sunitinib resistant	Phase 2	38	ORR 68%	On NCCN guidelines.	[39]
Nilotinib	Imatinib- and Sunitinib resistant	Phase 3 ( ENEST g3)	248	No difference in PFS or OS	Further trials	[40]
Sorafenib	Imatinib- and Sunitinib resistant	Phase 2	41	ORR 37.6%	On NCCN guidelines.	[41]
Dasatinib	Imatinib- and Sunitinib resistant	Phase 1	47	PR - 32%	Further trials	[42]

Abbreviations: TTP time to progression; ORR overall response rate; PR partial response.

ISSN: 1756-8722